Diedaqili Tablet Promotes Bony Fusion Accelerates Fracture Healing In Mice

Diedaqili tablet has been found effective for fracture healing in previous clinical studies. In a recent study, we investigated the effects of diedaqili tablet (DDQL) on bone fracture repair in mice. Adult C57BL/6 mice were subjected to transverse femoral fractures and administrated orally with a low dose (40.55mg/ ml), a high dose (162.18mg/ml) DDQL suspension and normal saline daily from day 1 after operation. The femur and blood of mice was analyzed by plain radiography, micro-computed tomography (Micro-CT), histology, biomechanical analysis, and serum Ca, P, and ALP test. The results demonstrated that DDQL can effectively improve the porosis of fracture end and bony union in the course of healing via Micro-CT and hematoxylin-eosin staining (HE staining) analysis. Consistent with morphological findings, biomechanical properties of fracture healing have also been demonstrated. And Diedaqili tablet has a dose-dependent effect. DDQL augmented the release of alkaline phosphatase (ALP) and phosphorus (P) into blood, indicating that it promoted mineralization of hypertrophic cartilage and woven bone growth simultaneously during bone healing. In summary, the preliminary experiment revealed that DDQL can improve bone formation via promoting osteogenic capability, calcium (Ca) and P metabolism, and subsequently accelerates fracture repair and bony fusion.